



## INDIA GLYCOLS LIMITED

Plot No. 2-B, Sector - 126, NOIDA-201304, Distt. Gautam Budh Nagar (Uttar Pradesh), Tel. : +91 (120) 6860000, 3090100, 3090200  
Fax : +91 (120) 3090111, 3090211, E-mail : [iglho@indiaglycols.com](mailto:iglho@indiaglycols.com), Website : [www.indiaglycols.com](http://www.indiaglycols.com)

IGL/SE/2025-26/66

26<sup>th</sup> November, 2025

**The Manager (Listing)**  
**BSE Limited**  
1<sup>st</sup> Floor, New Trading Ring,  
Rotunda Building, P.J. Towers,  
Dalal Street,  
Mumbai- 400 001

**The Manager (Listing)**  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (East)  
Mumbai – 400 051

**Scrip Code: 500201**

**Symbol: INDIAGLYCO**

Dear Sirs,

**Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) – Successful allotment of Equity Shares on Preferential Basis.**

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of the announcement on the captioned subject.

The same is also being hosted on the Company's website at [www.indiaglycols.com](http://www.indiaglycols.com).

This is for your information and record.

Thanking you,

Yours truly,

For **India Glycols Limited**

**Ankur Jain**  
**Head (Legal) & Company Secretary**  
**Encl: A/a**



## **India Glycols Limited announces successful allotment of Equity Shares on Preferential Basis**

**Noida, 26<sup>th</sup> November, 2025:** India Glycols Limited ("IGL"), (NSE: INDIAGLYCO) (BSE: 500201) is pleased to announce that pursuant to requisite statutory and regulatory approvals, IGL has, on 24<sup>th</sup> November, 2025, successfully allotted, on preferential basis 51,03,765 Equity Shares of Face Value Rs. 5/- each, at an issue price of Rs. 915/- per Equity Share (Including a premium of Rs. 910/-per Equity Share), aggregating to Rs. 466.99 Crore, for cash consideration, as approved earlier by the Board of Directors in its meeting held on 16<sup>th</sup> October, 2025 and subsequently by the Members at their Extraordinary General Meeting held on 12<sup>th</sup> November, 2025.

Of the newly issued Equity Shares, Kashipur Holdings Limited (KHL), part of the Promoter Group, was allotted 21,85,790 Equity Shares and 29,17,975 Equity Shares have been allotted to various funds and other investors belonging to the Non-Promoter category.

The Listing and Trading approval for the newly allotted shares is under process.

The funds raised from this preferential issue will be used to reduce IGL's overall debt including term loans and working capital by 31<sup>st</sup> March, 2026. The Company remains committed to further strengthening its financial position and will continue its endeavour to reduce its debt further. This financial focus will benefit all stakeholders and help IGL achieve sustainable growth and create stakeholder's value.

India Glycols Limited extends its sincere appreciation to all participating investors for their confidence in the Company's vision and long-term value creation plans. We remain committed to delivering sustainable performance and enhancing stakeholder value.

### **About India Glycols Limited**

India Glycols Limited, founded in 1983, is one of the leading manufacturers of Bio-based Specialties & Performance Chemicals (BSPC), Bio Fuel, Potable Spirits (PS) and Ennature Biopharma (EB). It is the first Company in the world to produce Ethylene Oxide (EO) / Mono Ethylene Glycol (MEG) from renewable Agro route based on molasses since 1989. IGL has a diversified portfolio with exposure in Bio-based Specialties, Bio-Polymers, Plant based APIs & Nutraceuticals, Potable Spirits, Gases, Biofuels, and others. IGL has a global presence and partners in various countries, with a rich legacy of over three decades in innovation and sustainability. IGL operates through its 3 state-of-the-art manufacturing facilities located in Kashipur, Gorakhpur and Dehradun, and exports to more than 40 countries across the globe.

Further, to continue value creation for its stakeholders, the Board of Directors in its meeting held on 16<sup>th</sup> May, 2025, has approved a Scheme of Arrangement ("Scheme") between the Company and Ennature Biopharma Limited and IGL Spirits Limited and their respective shareholders. Recently, the Company has received the requisite No-Objection of the Stock Exchanges, and the Company is now proceeding with the steps required for the approval of the Scheme from Hon'ble National Company Law Tribunal, Allahabad. The appointed date for the Scheme is 1<sup>st</sup> April, 2026.

For more details, please visit: <https://www.indiaglycols.com/>

### **Disclaimer:**

*This announcement contains forward looking statements. We cannot guarantee that these statements will be realised as these are based on certain assumptions and factors. We undertake no obligation to publicly update any forward looking statements to reflect future events or circumstances.*